Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with ...

Lilly is deploying biopharma’s most powerful AI Factory, built on the world’s first DGX B300 SuperPOD with over 1,000 ...

An agreement has been signed between the Sindh government’s Department of Empowerment of Persons with Disabilities and NED University to launch the project as a pilot scheme later this month. In the ...

Orchestra BioMed enrols first patients in Virtue SAB pivotal investigational device exemption coronary trial: New Hope, Pennsylvania Wednesday, October 29, 2025, 18:00 Hrs [IST] O ...

Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On October 28, 2025, Orchestra BioMed Holdings announced a new strategic agreement ...

New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a ...

After vocal cord surgery, many patients develop stiff vocal folds that impact their ability to speak. Hydrogels can help ...

From ingestible pills that track gut health to smart bandages that can autonomously provide required treatment to wounds, ...

Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with ...

The rapid advancement of sensing and artificial intelligence (AI) systems has paved the way for the introduction of ...

Zanos, PhD, head of the Northwell's Division of Heath AI, and associate professor in the Feinstein Institutes' Institute of Bioelectronic Medicine and the Institute of Health System Science.

Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured ...